Prevail Therapeutics to Present at Bank of America Global Research Virtual Health Care Conference 2020
May 05, 2020 16:05 ET
|
Prevail Therapeutics
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting
April 29, 2020 09:09 ET
|
Prevail Therapeutics
Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Design Overview for Planned Phase 1/2...
Prevail Therapeutics to Present at AAT-AD/PD Focus Meeting 2020: Advances in Alzheimer’s and Parkinson’s Therapies
March 31, 2020 07:00 ET
|
Prevail Therapeutics
Design of PROPEL Phase 1/2 Clinical Trial for Parkinson’s Disease Patients with GBA1 Mutations to Be Presented Preclinical Data of PR001 for Parkinson’s Disease with GBA1 Mutations and PR006 for...
Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
March 26, 2020 07:00 ET
|
Prevail Therapeutics
Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations Preparations Underway to Initiate PROVIDE Phase 1/2 Trial of PR001 for Treatment of Type...
Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation
March 24, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations
March 03, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation
March 02, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Present at Upcoming Conferences
February 21, 2020 08:30 ET
|
Prevail Therapeutics
NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA
February 12, 2020 07:00 ET
|
Prevail Therapeutics
Orphan Drug Designation Granted for Treatment of Gaucher Disease Rare Pediatric Disease Designation Granted for Treatment ofNeuronopathic Gaucher Disease NEW YORK, Feb. 12, 2020 (GLOBE...
Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020
February 06, 2020 08:30 ET
|
Prevail Therapeutics
NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...